Safety and Efficacy of I-020502 in Meshed Skin Autografting

NCT00471939 ↗

Phase 2 Completed 10 enrolled Kuros Biosurgery AG Baxter BioScience · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

This is a phase II, multi-centre, controlled study comparing the safety and tolerability on wound healing following an application of I-020502 in a concentration of 1μg/mL TG-PDGF.AB versus staples applied in the same patient to burn areas requiring autologous meshed skin grafting.

Timeline

Start: 2007-04
Primary completion: 2007-12
Completion: 2009-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	I-020502	Unknown	1 ug/ml	Topical

Indications

No indication recorded.